CVD risk assessment: Do we need the metabolic syndrome or better global cardiometabolic risk calculators?

International Journal of Obesity

Volumn 32, Issue , 2008, Pages S1-S4

  Despres J P ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; APOLIPOPROTEIN B; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ATHEROGENESIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PRACTICE; CONFERENCE PAPER; CORONARY RISK; CORRELATION ANALYSIS; DIABETES MELLITUS; DIETARY INTAKE; DISEASE SEVERITY; DYSLIPIDEMIA; FOLLOW UP; GENETIC AND FAMILIAL DISORDERS; HEALTH PRACTITIONER; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; MATHEMATICAL MODEL; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SITTING; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

CARDIOVASCULAR DISEASES; HUMANS; METABOLIC SYNDROME X; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 43449101212     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2008.27     Document Type: Editorial

References (16)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.
2. Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedersen TR et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93: 136–141.
3. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110: 1251–1257.
4. Katzmarzyk PT, Church TS, Blair SN. Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med 2004; 164: 1092–1097.
5. Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levelsFa prospective and cross-sectional evaluation. Atherosclerosis 2002; 165: 285–292.
6. Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DS, Haffner SM et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414–419.
7. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–689.
8. Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066–3072.
9. Mule G, Nardi E, Cottone S, Cusimano P, Volpe V, Piazza G et al. Influence of metabolic syndrome on hypertension-related target organ damage. J Intern Med 2005; 257: 503–513.
10. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881–887.
11. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289–2304.
12. Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care 2003; 26: 3093–3101.
13. Schlessinger L, Eddy DM. Archimedes: a new model for simulating health care systemsFthe mathematical formulation. J Biomed Inform 2002; 35: 37–50.
14. Meigs JB, D’Agostino Sr RB, Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes 1997; 46: 1594–1600.
15. Després JP, Lemieux I, Alméras N. Abdominal obesity and the metabolic syndrome. In: Bray GA, Ryan DH (eds). Overweight and the Metabolic Syndrome: From Bench to Bedside, vol. 8. Springer Science+Business Media Inc.: New York, 2006, pp 137–152.
16. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Alméras N et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia, hyperapolipoprotein B, small, dense LDL) in men? Circulation 2000; 102: 179–184.